Meeting
2019 ASCO Annual Meeting
Neutrophil to Lymphocyte ratio (NLR): A prognostic marker in melanoma patients receiving immunotherapy.
Authors
Richard Thomas O'Dwyer
Mater Misericordiae University Hospital, Dublin, Ireland
Richard Thomas O'Dwyer , Colum Dennehy , Jane Sze Yin Sui , Catherine Margaret Kelly , Paula Calvert , John McCaffrey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9573)
DOI
10.1200/JCO.2019.37.15_suppl.9573
Abstract #
9573
Poster Bd #
144
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Hematological profile: A prognosis tool in melanoma patients treated with immunotherapy.
First Author: Soraia Lobo Martins
Poster
2022 ASCO Annual Meeting
Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy.
First Author: Deepak Bhamidipati
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Association of the neutrophil-to-lymphocyte ratio prior to checkpoint blockade immunotherapy (CBI) or radiation plus CBI with overall survival in melanoma patients.
First Author: Terence Duane Rhodes
Poster
2024 ASCO Annual Meeting
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.
First Author: Alireza Mansouri